Affiliated Sites
  • Clinicians Network Payer Bioinformatics
Be The Match

Javascript disabled. This site requires JavaScript How to enable JavaScript.

You are using an outdated browser. Please upgrade your browser to improve your experience.

Close

NMDP

Be The Match
  • About Us
  • E-News Sign Up
  • My Cart
  • Transplant Indications and Outcomes
    • HLA Today
    • Disease-Specific Indications and Outcomes
      • AML - Adult
      • AML - Pediatric
      • ALL - Adult
      • ALL - Pediatric
      • MDS
      • CML
      • CLL
      • NHL
      • Hodgkin Lymphoma
      • Multiple Myeloma
      • Severe Aplastic Anemia & Marrow Failure
      • Sickle Cell Disease
      • Immune Deficiency Diseases
      • Inherited Metabolic Disorders
      • Thalassemia
      • Other Diseases
      • Myeloproliferative Neoplasms
    • Additional Outcomes
      • Unrelated vs. Sibling Donor Outcomes
      • Older Patient Outcomes
      • Timing Impact on Outcomes
    • Eligibility
    • Referral Timing Guidelines
    • Order Kits
    • HLA Typing for Family Members
  • Transplant Therapy and Donor Matching
    • Cell Sources
    • HLA Typing and Matching
    • Donor or Cord Blood Search Process
      • Likelihood of Finding a Match
      • Preliminary Search Request
    • Jason Carter Clinical Trials Program
  • Post-Transplant Care
    • Early Complications
    • Vaccinations
    • Long-Term Care Guidelines
      • Pediatric Considerations
    • Chronic GVHD
      • Skin
      • Nails
      • Scalp and Body Hair
      • Eyes
      • Mouth
      • Lungs
      • Muscles, Fascia, Joints
      • Hematopoietic & Immune
      • GI Tract
      • Liver
      • Genitalia
      • Other
    • Post-Transplant Guidelines
  • Medical Education & Research
    • Browse News
    • Browse Research
      • Mismatched donor sources may fill an unmet need for patients without fully matched family or unrelated donors
      • Hematopoietic cell donor type may not impact quality of life post-transplant
      • Novel three-drug combination improves GVHD-free and relapse-free survival and relapse after allogeneic transplant
      • Long-term risks of hematological malignancy, autoimmune or thrombotic events do not differ in bone marrow and filgrastim-mobilized PBSC donors
      • Socioeconomic status but not race and ethnicity is likely associated with chronic GVHD outcomes after allogeneic HCT
      • Linkage across research databases may provide a more complete understanding of HCT patient outcomes
      • Race and ethnicity matching may not impact umbilical cord blood transplant patient outcomes
    • Education Catalog
      • Predicting and Addressing Relapse After HCT
      • After the Results Quality of Life Pre- and Post-Transplant
    • Materials Catalog
    • HCT Presentation Slides
    • About Our Research
    • Transplant Enews
  • Resources
    • Patient Resources
    • Financial Resources
    • Obstetrician Resources
    • Technique Videos
    • Umbilical Cord Blood Collection Training for Public Donation
    • Local Provider Partnership Program
  • Browse News
  • Browse Research
  • Education Catalog
  • Materials Catalog
  • HCT Presentation Slides
  • About Our Research
  • Transplant Enews

  • Medical Education & Research
  • Browse Research
  • Email
  • Print This Page

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma
+ More Topics

Subscribe to E-News

Receive new research summaries monthly.

Subscribe Now

Related Resources

Browse News
CIBMTR Research
Education Activities
Back to Top

Recent Research

Stay up-to-date on the advancing field of HCT with short summaries and links to the most relevant published research.

  • Prognostic factors identified for MDS patients most likely to benefit from induction chemotherapy after HMA failure

    September 2018

    Researchers identified several prognostic factors for patients with myelodysplastic syndromes (MDS) who would most benefit from induction chemotherapies as a bridge to allogeneic hematopoietic cell transplantation (HCT) after hypomethylating agent (HMA) failure. (Ball B, et al. Blood Advances)

    Learn which prognostic factors led to higher response rates and overall survival

    Read More

  • Disease Risk Index is Important Prognostic Factor for Older HCT Patients

    September 2017
    He F, et al. Biol Blood Marrow Transplant – A study of 196 patients age 60-75 years with hematologic malignancies undergoing reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) has found that the Disease Risk Index (DRI) score is a significant prognostic factor for post-transplant relapse, treatment failure and mortality.

    Read More

  • Immunoglobulin Significantly Reduces Chronic GVHD Rates

    July 2017
    Finke J, et al. Lancet Haematol – Anti-human-T-lymphocyte immunoglobulin (ATLG) significantly lowers chronic graft-versus-host disease (GVHD) rates and reduces risks associated with long-term immune suppression, according to a long-term randomized study of 201 patients undergoing hematopoietic cell transplantation (HCT).

    Read More

  • New Pre-HCT Counseling Recommendations to Preserve Fertility

    May 2017
    Dalle J-H, et al. Bone Marrow Transplant – In this report, a panel of transplant experts discuss state-of-the-art fertility preservation options available to adolescents and young adults who are considering hematopoietic cell transplantation (HCT).

    Read More

  • Improved HCT Outcomes for Fit Patients with MDS/AML After Standard Conditioning

    March 2017
    Scott BL, et al. J Clin Oncol – This randomized phase III trial of 272 adults with myelodysplastic syndromes (MDS) and acute myelogenous leukemia (AML) found that patients with hematopoietic cell transplantation (HCT) comorbidity index scores ≤4 and with <5% marrow myeloblasts had better relapse-free survival (RFS) after HCT with myeloablative conditioning (MAC), than after reduced-intensity conditioning (RIC).

    Read More

  • Results Show Non-Myeloablative Haploidentical Transplants Can Be Effective in Pediatric and Young Adult Patients

    January 2017
    Klein OR, et al. Biol Blood Marrow Transplant – For pediatric and young adult patients who are ineligible for myeloablative transplant, non-myeloablative haploidentical bone marrow transplantation using post-transplant cyclophosphamide can be a safe and effective treatment, according to a single-center study of 40 transplant recipients.

    Read More

  • One-Year OS of 86% Achieved with Unrelated Donor HCT for Children with SCD

    October 2016
    Shenoy S, et al Blood – This multi-center phase II trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) analyzed outcomes of 29 children (age range 6-19 years) with sickle cell disease (SCD) who underwent reduced-intensity conditioning unrelated donor hematopoietic cell transplantation (HCT) between 2008 and 2014.

    Read More

  • HCT Outcomes in Older Patients with SAA Comparable to Younger Patients

    July 2016
    Shin SH, et al. Bone Marrow Transplant – A study of 117 adults with severe aplastic anemia (SAA) undergoing lower-intensity HCT using HLA-matched sibling donors found that transplant outcomes were comparable between older patients (>40 years) and younger patients (≤40 years).

    Read More

  • HCT Yields Over 80% 3-Year Survival and Low Relapse in High-Risk FL Patients

    May 2016
    Laport GG, et al. Biol Blood Marrow Transplant – Hematopoietic cell transplantation (HCT) using reduced-intensity conditioning with rituximab yields excellent survival in high-risk patients with follicular lymphoma (FL), according to results of a prospective phase II study by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

    Read More

  • Haploidentical, Unrelated Donor HCT Outcomes Comparable in Lymphoma

    March 2016
    Kanate AS, et al. Blood – Reduced-intensity HCT using haploidentical or matched unrelated donors (URD) yields comparable outcomes, according to a study of 917 adults transplanted for lymphoma.

    Read More

  • Improved Quality of Life, No GVHD after HCT in Adults with Sickle Cell Disease

    March 2016
    Saraf SL, et al. Biol Blood Marrow Transplant – HCT using an innovative conditioning regimen can result in a cure with marked improvements in quality of life for patients with high-risk sickle cell disease, according to a study of 13 adults transplanted using matched related donors.

    Read More

  • ATG Significantly Lowers Rate of Chronic GVHD

    January 2016
    Kröger N, et al. N Engl J Med – Adding anti-thymocyte globulin (ATG) to a myeloablative conditioning regimen can cut the 2-year rate of chronic GVHD in half, according to results of a multi-center, prospective randomized trial of 168 patients transplanted for acute leukemias.

    Read More

  • Higher Relapse-Free Survival with Myeloablative HCT in Patients with AML and MDS

    December 2015
    Scott BL, et al. ASH abstract oral presentation, December 2015 – A phase III randomized trial presented at the ASH Annual Meeting has shown that although reduced-intensity regimens have lower treatment-related mortality (TRM), they also incur higher relapse rates.

    Read More

  • Comparable Outcomes in Unrelated Donor vs. Haploidentical HCT with Cyclophosphamide

    December 2015
    Mussetti A, et al. ASH abstract oral presentation, December 2015 – Lower-intensity hematopoietic cell transplantation (HCT) using haploidentical donors and post-transplant cyclophosphamide for GVHD prophylaxis can achieve outcomes comparable to HLA-matched unrelated donor transplants, according to results of a retrospective study of 917 adults with Hodgkin or Non-Hodgkin lymphoma.

    Read More

  • Survival 80% or Higher with Allogeneic HCT after Failed Autologous HCT for Lymphoma

    December 2015
    Rezvani AR, et al. Bone Marrow Transplant – In a study of 47 patients with lymphoma who had failed prior autologous hematopoietic cell transplantation (HCT), 3-year overall survival was 81% after allogeneic HCT with a conditioning regimen using total lymphoid irradiation and antithymocyte globulin (TLI-ATG).

    Read More

  • Survival 65% or Higher in HCT for Progressive or Refractory Follicular Lymphoma

    December 2015
    Yano S, et al. Bone Marrow Transplant – A multi-center retrospective study of reduced-intensity hematopoietic cell transplantation (HCT) in 46 adults with follicular lymphoma has shown that this therapy can result in a 5-year overall survival (OS) of 71.6%.

    Read More

  • Better HCT Outcomes in Younger Adults with T-Cell ALL

    December 2015
    Cahu X, et al. Bone Marrow Transplant – This long-term, retrospective study of 601 adults with T-cell acute lymphoblastic leukemia (ALL) has demonstrated that hematopoietic cell transplantation (HCT) has better outcomes when total body irradiation (TBI) is used for pre-transplant conditioning compared to chemotherapy-only conditioning, but only in adults age <35 years.

    Read More

  • 95% One-Year HCT Survival for Adults with Sickle Cell Disease

    December 2015
    Krishnamurti L, et al. ASH abstract oral presentation, December 2015 – One-year overall and event-free survival probabilities were both 95% after hematopoietic cell transplantation (HCT) in adults with sickle cell disease (SCD), according to results of a multi-center study reported at the ASH Annual Meeting.

    Read More

  • Allogeneic HCT Better than Autologous HCT for Progression-Free Survival in Follicular Lymphoma

    September 2015
    Klyuchnikov E, et al. Biol Blood Marrow Transplant – In adults with follicular lymphoma (FL), reduced-intensity allogeneic hematopoietic cell transplantation (HCT) yields better long-term survival compared to autologous HCT, according to results of a study of 518 rituximab-treated patients with FL transplanted between 2000 and 2012.

    Read More

  • Level of HLA Match Affects Outcomes in Reduced-Intensity HCT

    June 2015
    Verneris MR, et al. Biol Blood Marrow Transplant — This retrospective, large-scale study examined the effect of HLA match on reduced-intensity, unrelated donor transplantation.

    Read More

  • Comparable Survival in Cord Blood, Mismatched Unrelated HCT for AML

    May 2015
    Malard F, et al. Biol Blood Marrow Transplant — A long-term study of 651 adults with acute myeloid leukemia (AML) receiving reduced-intensity (RIC) or nonmyeloablative conditioning (NMA) transplantation has found comparable four-year survival with umbilical cord blood and mismatched unrelated donors: 47.9% vs. 50.5%, respectively (p=0.81).

    Read More

  • Long-Term Outcomes after HCT for Mantle Cell Lymphoma

    April 2015
    Vaughn J, et al. Oral presentation, BMT Tandem Meetings — A study of 70 patients with mantle cell lymphoma (MCL) undergoing non-myeloablative hematopoietic cell transplantation (HCT) demonstrated that a majority can achieve 5-year survival and can discontinue immunosuppressive medications.

    Read More

  • Excellent HCT Outcomes in Fanconi Anemia without Radiation

    April 2015
    Bonfim C, et al. Oral presentation, BMT Tandem Meetings — Five-year 5-year overall survival was 87% in a single-center study of 103 consecutive patients with Fanconi anemia who underwent allogeneic bone marrow transplantation between 2003 and 2014 using chemotherapy-only conditioning.

    Read More

  • Review: Reduced-Intensity HCT in Adults with AML

    March 2015
    Reshef R, et al. Bone Marrow Transplant — In this review, the authors discuss the current status of reduced-intensity conditioning (RIC) hematopoietic cell transplantation (HCT) in treating acute myelogenous leukemia (AML).

    Read More

  • No Impact of Patient Age on Survival in Reduced-Intensity HCT

    March 2015
    Federmann B, et al. Bone Marrow Transplant — Patient age has no significant impact on survival, according to results of a retrospective study of 151 patients aged ≥60 undergoing reduced-intensity allogeneic HCT with related and unrelated donors between 2000 and 2012.

    Read More

  • Marrow, Peripheral Blood Yield Comparable 5-year Survival in Reduced-Intensity HCT

    January 2015
    Eapen M, et al. J Clin Oncol — This study examining the outcomes of peripheral blood stem cell (PB) and bone marrow (BM) transplants using reduced-intensity conditioning found no significant differences in outcomes based on graft source.

    Read More

  • Treosulfan-Based Conditioning and HCT for Nonmalignant Diseases

    December 2014
    Burroughs LM, et al. Biol Blood Marrow Transplant — Patients with nonmalignant diseases undergoing hematopoietic cell transplantation using treosulfan-based conditioning can achieve a 2-year survival of 90%, according to a prospective multi-center trial of 31 transplants.

    Read More

  • Long-Term Impact of TBI on Cognitive Functioning in Pediatric HCT

    November 2014
    Willard VW, et al. J Clin Oncol — Using total-body irradiation (TBI) in pre-transplant conditioning regimens lowers cognitive ability, according to a study of 315 pediatric hematopoietic cell transplant (HCT) recipients.

    Read More

  • BMT CTN Study to Compare HCT to Hypomethylating Agents to Treat MDS

    October 2014
    Saber W, et al. Biol Blood Marrow Transplant — This report outlines the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) trial to compare outcomes of reduced-intensity hematopoietic cell transplantation (HCT) in high-risk patients, 50-75 years of age, with myelodysplastic syndromes (MDS) with outcomes in patients with similar risk receiving novel nontransplant therapies such as hypomethylating agents.

    Read More

  • Review Series in Blood Journal: Advances in HCT

    August 2014
    Negrin RS, et al. Blood — Scientific and clinical translational research highlighting treatment advances in the field of HCT are available in five review articles in Blood.

    Read More

  • Review: Factors Affecting Selection of a Pre-HCT Conditioning Regimen

    June 2014
    Gyurkocza B, et al. Blood — In this review, the authors outline how a patient’s diagnosis, disease status, donor availability, graft source, and patient-related factors such as the presence or absence of comorbid conditions all influence the choice of a pre-transplant conditioning regimen.

    Read More

  • Encouraging Progression-Free Survival in HCT for Older NHL Patients

    April 2014
    McClune BL, et al. Biol Blood Marrow Transplant - This CIBMTR study analyzed outcomes of 1,248 patients age ≥40 years undergoing reduced-intensity or non-myeloablative hematopoietic cell transplantation (HCT) for aggressive (n=668) or indolent (n=580) non-Hodgkin lymphoma (NHL).

    Read More

  • Pre-Transplant ATG Protects against GVHD in MDS

    April 2014
    Duléry R, et al. Biol Blood Marrow Transplant - In this study of 242 consecutive patients undergoing hematopoietic cell transplantation (HCT) for progressive myelodysplastic syndrome (MDS), outcomes were compared between patients receiving rabbit antithymocyte globulin (ATG; n=93) and those who did not (n=149).

    Read More

  • Reduced-Intensity HCT for Chronic Granulomatous Disease

    February 2014
    Güngör T, et al. Lancet -- Reduced-intensity allogeneic HCT for chronic granulomatous disease can lead to two-year survival rates exceeding 95%, according to the results of a prospective multi-center trial.

    Read More

  • Early Transplant Best in Chemotherapy-Sensitive MCL

    January 2014
    Fenske TS, et al. J Clin Oncol - For patients with chemotherapy-sensitive mantle cell lymphoma (MCL), the optimal timing for either reduced-intensity HCT (RIC-HCT) or autologous HCT (auto-HCT) is early in the disease course, according to a recent study.

    Read More

  • Peri-Transplant Rituximab in Lymphoma Can Lead to Durable Event-Free Survival

    December 2013
    Sauter CS, et al. Biol Blood Marrow Transplant - Non-myeloablative transplantation incorporating peri-transplant-rituximab can lead to a two-year event-free survival (EFS) of 72%, according to results of a prospective trial of 51 patients with CD20+ B-cell non-Hodgkin lymphoma.

    Read More

  • Review: Strategies to Improve Outcomes of Unrelated Donor PBSC Transplants

    December 2013
    Sohn SK, et al. Transfusion - The authors of this review note that because of the higher incidence of graft-versus-host disease (GVHD) in peripheral blood stem cell (PBSC) transplant compared to marrow transplant, strategies need to be different for the two stem cell grafts.

    Read More

  • Prior Therapy Does Not Affect Transplant Outcomes in High-Risk MDS

    December 2013
    Oran B, et al. ASH abstract oral presentation – Therapies prior to hematopoietic cell transplantation (HCT) have no effect on outcomes in patients with high-risk myelodysplastic syndromes (MDS), according to a single-center study of 291 patients.

    Read More

  • IV Busulfan Better Than TBI in HCT for AML in CR1

    October 2013
    Copelan EA, et al. Blood - Hematopoietic cell transplant (HCT) patients with acute myeloid leukemia (AML) in first complete remission (CR1) conditioned with intravenous busulfan (IV-Bu) have better outcomes than those receiving total body irradiation (TBI).

    Read More

  • IV Busulfan Better Than TBI in Pre-Transplant Conditioning

    October 2013
    Bredeson C, et al. Blood - Hematopoietic cell transplant (HCT) patients conditioned with intravenous busulfan (IV-BU) have better outcomes than those receiving total body irradiation (TBI), according to results of a prospective cohort study of 1,483 patients transplanted for myeloid malignancies.

    Read More

  • Lower Chronic GVHD in Double Cord Blood HCT

    August 2013
    Malard F, et al. Leukemia - Double cord blood and 9/10 matched unrelated donor reduced-intensity transplants have similar outcomes, but using cord blood results in a significantly lower incidence of chronic graft-versus-host disease (GVHD), according to a study of 152 patients (median age 53 years) transplanted for hematological malignancies.

    Read More

  • Outcomes for HCT in Patients Over Age 70

    July 2013
    Brunner AM, et al. Biol Blood Marrow Transplant - Select older patients can undergo HCT, according to results of a study of 54 consecutive patients >70 years undergoing reduced-intensity transplantation between 2007 and 2012 at Massachusetts General Hospital (n=14) or the Dana-Farber Cancer Institute (n=40).

    Read More

  • Similar Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts in AML

    July 2013

    de Latour RP, et al. Biol Blood Marrow Transplant - Reduced-intensity conditioning HCT in patients 50 years and older with acute myelogenous leukemia (AML) in complete remission has similar outcomes using sibling donors, unrelated donors, and cord blood units.

    Read More

  • Review: Allogeneic HCT for Diffuse Large B Cell Lymphoma

    June 2013

    Klyuchnikov E, et al. Bone Marrow Transplant - In this review article, the authors note that despite overall improvements in outcomes of patients with diffuse large B cell lymphoma (DLBCL), approximately 30-40% will develop relapsed or refractory disease.

    Read More

  • Comparable Outcomes in AML/MDS Using Related, Unrelated Donors

    May 2013
    Robin M, et al. Bone Marrow Transplant - Matched unrelated or matched sibling donors can lead to comparable transplant survival, according to a single-center research study of 108 patients with AML (n=63) and MDS (n=45).

    Read More

  • Review: Minimal Residual Disease in Acute Leukemia

    May 2013

    Buckley SA, et al. Bone Marrow Transplant, Campana D, et al. Br J Haematol - In these two review articles on minimal residual disease (MRD) in patients with acute leukemia, the authors discuss the recent research showing that the likelihood of relapse after transplant is directly associated with levels of MRD before transplant.

    Read More

  • No Clinical Benefit in Adding Radioimmunotherapy to BEAM Conditioning in Autologous HCT for Relapsed DLBCL

    March 2013
    Vose JM, et al. J Clin Oncol — In patients with relapsed diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (HCT), adding radioimmunotherapy to the standard BEAM conditioning regimen provides no clinical benefit, according to results from a randomized phase III clinical trial conducted by the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).

    Read More

  • Graft-Versus-Tumor Effects in Advanced Malignancies

    March 2013

    Storb R, et al. J Clin Oncol - A study of a minimal-intensity pre-transplant conditioning regimen consisting of low-dose total body irradiation with or without fludarabine has shown that it can induce strong graft-versus-tumor (GVT) effects leading to lasting remissions in 45% to 75% of patients.

    Read More

  • HCT for Chemorefractory Mantle Cell Lymphoma

    February 2013
    Hamadani M, et al. Biol Blood Marrow Transplant - This study examined 202 adults with chemotherapy-unresponsive mantle cell lymphoma (MCL) who underwent allogeneic HCT between 1998 and 2010 and whose outcomes were reported to CIBMTR (Center for International Blood and Marrow Transplant Research).

    Read More

  • Myeloablative HCT Improves Survival in Younger Adults with ALL in First Remission

    January 2013

    Gupta V, et al. Blood - A meta-analysis combining data from 13 studies including 2,962 adults has shown that allogeneic, but not autologous, hematopoietic cell transplantation (HCT) improves survival in younger adults with acute lymphoblastic leukemia (ALL) in first complete remission.

    Read More

  • Email
  • Print This Page

Transplant Indications and Outcomes

  • HLA Today
  • Disease-Specific Indications and Outcomes
  • Additional Outcomes
  • Eligibility
  • Referral Timing Guidelines
  • Order Kits
  • HLA Typing for Family Members

Transplant Therapy and Donor Matching

  • Cell Sources
  • HLA Typing and Matching
  • Donor or Cord Blood Search Process
  • Jason Carter Clinical Trials Program

Resources

  • Patient Resources
  • Financial Resources
  • Obstetrician Resources
  • Technique Videos
  • Umbilical Cord Blood Collection Training for Public Donation
  • Local Provider Partnership Program

Contact Us

About Us

Our Websites

bethematch.org
BeTheMatch.org Information and support for patients, donors and supporters of our mission.
BeTheMatchBioTherapies.com
BeTheMatchBioTherapies.com Proven solutions for organizations developing and delivering new cellular therapies
CIBMTR.org
CIBMTR.org Transplant research, clinical studies, publications and outcomes data for researchers and clinicians.
National Marrow Donor Program —
Entrusted and under contract to operate the C.W. Bill Young Cell Transplantation Program, including Be The Match Registry®.
Copyright © 1996-2023 National Marrow Donor Program. All Rights Reserved. Terms of Use | Privacy Policy | Trademark & Copyright

Choose a Topic

  • All Topics
  • Patient Eligibility
  • AML
  • Unrelated Donor HCT
  • Post-Transplant
  • CIBMTR Publications
  • GVHD
  • ALL
  • Lymphomas and CLL
  • Preparative Regimens
  • Pediatric HCT
  • Older Patient HCT
  • MDS
  • Non-Malignant Disorders
  • BMT CTN Publications
  • Cord Blood
  • Multiple Myeloma
  • Sickle Cell Disease
  • HLA Matching
  • ASH 2015
  • ASH 2017
  • ASH 2016
  • ASH 2020
  • CML
  • ASH 2018
  • Neuroblastoma